MonashHEART, Southern Health, Monash Medical Centre, Clayton, Victoria, Australia.
EuroIntervention. 2012 Sep;8 Suppl Q:Q70-4. doi: 10.4244/EIJV8SQA12.
As a result of recent randomised controlled trials and registry observations, transcatheter aortic valve replacement (TAVR) enjoys growing appeal for the treatment of patients at high or extreme risk from surgical aortic valve replacement. However, the current technologies and techniques have important limitations, including risk of stroke, vascular complications and paravalvular aortic regurgitation, which may in turn influence survival. While careful patient selection and screening may improve outcomes, new valve designs and iterations are required. The Lotus aortic valve replacement system is a new fully repositionable device designed to facilitate more precise delivery and minimise paravalvular regurgitation. The safety and efficacy of the Lotus valve are being studied systematically in the REPRISE clinical trial programme.
由于最近的随机对照试验和注册观察，经导管主动脉瓣置换术（TAVR）在治疗外科主动脉瓣置换术高危或极高危患者方面越来越受欢迎。然而，目前的技术和技术存在重要的局限性，包括中风风险、血管并发症和瓣周主动脉反流，这反过来可能影响生存率。虽然仔细的患者选择和筛选可能会改善结果，但需要新的瓣膜设计和迭代。莲花主动脉瓣置换系统是一种新的完全可重新定位的装置，旨在更精确地输送并最大限度地减少瓣周反流。莲花瓣膜的安全性和有效性正在 REPRISE 临床试验计划中进行系统研究。
